Your browser doesn't support javascript.
loading
'Quitlink': Outcomes of a randomised controlled trial of peer researcher facilitated referral to a tailored quitline tobacco treatment for people receiving mental health services.
Baker, Amanda L; McCarter, Kristen; Turner, Alyna; Segan, Catherine; Castle, David; Brophy, Lisa; Borland, Ron; Kelly, Peter J; Bonevski, Billie; Baird, Donita; Filia, Sacha; Attia, John; Szwec, Stuart; Palazzi, Kerrin; White, Sarah L; Williams, Jill M; Wrobel, Anna L; Ireland, Andrew; Saxby, Karinna; Ghijben, Peter; Petrie, Dennis; Sweeney, Rohan.
Afiliação
  • Baker AL; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.
  • McCarter K; School of Psychological Sciences, College of Engineering, Science and Environment, University of Newcastle, Callaghan, NSW, Australia.
  • Turner A; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.
  • Segan C; IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.
  • Castle D; Cancer Council Victoria, Melbourne, VIC, Australia.
  • Brophy L; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Borland R; Centre for Complex Interventions, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, ON, Canada.
  • Kelly PJ; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Bonevski B; Social Work and Social Policy, School of Allied Health, Human Services and Sport, La Trobe University Melbourne, VIC, Australia.
  • Baird D; Cancer Council Victoria, Melbourne, VIC, Australia.
  • Filia S; Centre for Mental Health, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Attia J; Illawarra Health and Medical Research Institute and the School of Psychology, University of Wollongong, Wollongong, NSW, Australia.
  • Szwec S; Flinders Health and Medical Research Institute (FHMRI), College of Medicine & Public Health, Flinders University, Bedford Park, SA, Australia.
  • Palazzi K; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.
  • White SL; Cancer Council Victoria, Melbourne, VIC, Australia.
  • Williams JM; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.
  • Wrobel AL; Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Ireland A; Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Saxby K; Cancer Council Victoria, Melbourne, VIC, Australia.
  • Ghijben P; Division of Addiction Psychiatry, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • Petrie D; IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, VIC, Australia.
  • Sweeney R; Orygen, Parkville, VIC, Australia.
Aust N Z J Psychiatry ; 58(3): 260-276, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37353970
ABSTRACT

OBJECTIVE:

The aim of this study was to test the effectiveness of a tailored quitline tobacco treatment ('Quitlink') among people receiving support for mental health conditions.

METHODS:

We employed a prospective, cluster-randomised, open, blinded endpoint design to compare a control condition to our 'Quitlink' intervention. Both conditions received a brief intervention delivered by a peer researcher. Control participants received no further intervention. Quitlink participants were referred to a tailored 8-week quitline intervention delivered by dedicated Quitline counsellors plus combination nicotine replacement therapy. The primary outcome was self-reported 6 months continuous abstinence from end of treatment (8 months from baseline). Secondary outcomes included additional smoking outcomes, mental health symptoms, substance use and quality of life. A within-trial economic evaluation was conducted.

RESULTS:

In total, 110 participants were recruited over 26 months and 91 had confirmed outcomes at 8 months post baseline. There was a difference in self-reported prolonged abstinence at 8-month follow-up between Quitlink (16%, n = 6) and control (2%, n = 1) conditions, which was not statistically significant (OR = 8.33 [0.52, 132.09] p = 0.131 available case). There was a significant difference in favour of the Quitlink condition on 7-day point prevalence at 2 months (OR = 8.06 [1.27, 51.00] p = 0.027 available case). Quitlink costs AU$9231 per additional quit achieved.

CONCLUSION:

The Quitlink intervention did not result in significantly higher rates of prolonged abstinence at 8 months post baseline. However, engagement rates and satisfaction with the 'Quitlink' intervention were high. While underpowered, the Quitlink intervention shows promise. A powered trial to determine its effectiveness for improving long-term cessation is warranted.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Abandono do Hábito de Fumar / Serviços de Saúde Mental Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Abandono do Hábito de Fumar / Serviços de Saúde Mental Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article